greeksoup/ stock research

Biogen (BIIB) Q3 FY2025 earnings: revenue $2.5 billion, up 2.8% on the year

Biogen Inc. (BIIB) reported revenue of $2.5 billion for Q3 FY2025, the quarter ended 30 September 2025, up 2.8% on the same quarter a year earlier. Net income was $466 million, up 20.1% on the year, and diluted earnings per share $3.17. The figures are the company's own, from the 10-Q it filed with the SEC on 30 October 2025.

Revenue
$2.5 billion
+2.8% on the year · -4.2% on the quarter
Q4 FY2023Q3 FY2025
Operating margin
22.0%
18.3% a year earlier
Q4 FY2023Q3 FY2025
Net income
$466 million
+20.1% on the year · -26.5% on the quarter
Q4 FY2023Q3 FY2025
Diluted EPS
$3.17
+19.2% on the year · -26.8% on the quarter
Q4 FY2023Q3 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Revenue2,5352,6462,466-4.2%+2.8%
Cost of revenue674605639+11.5%+5.6%
Gross profit1,8602,0401,827-8.8%+1.8%
Gross margin73.4%77.1%74.1%
Research and development436399516+9.3%-15.5%
Selling, general and administrative595584588+1.9%+1.1%
Operating income557744451-25.1%+23.6%
Operating margin22.0%28.1%18.3%
Interest expense67.472.659.8-7.2%+12.7%
Pre-tax income557744451-25.1%+23.6%
Income tax90.810962.5-16.8%+45.3%
Effective tax rate16.3%14.7%13.9%
Net income466635388-26.5%+20.1%
Net margin18.4%24.0%15.8%
Diluted EPS$3.17$4.33$2.66-26.8%+19.2%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Operating cash flow1,272161936+690.9%+36.0%
Capital expenditure46.226.635.0+73.7%+32.0%
Free cash flow1,226134901+813.1%+36.2%
Free cash flow margin48.4%5.1%36.5%
Cash from investing-35.1-57.0-1,181
Cash from financing-130-11.7-6.6
Depreciation and amortisation202194183+4.1%+10.6%
Share-based compensation75.374.9-75.0+0.5%
Diluted shares, weighted147m147m146m+0.3%+0.7%
Shares outstanding at period end147m147m146m+0.1%+0.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2025Q2 FY2025Q3 FY2024On the quarterOn the yearLast 8 quarters
Shareholders' equity18,20817,63416,359+3.3%+11.3%
Debt6,2856,2846,294+0.0%-0.1%
Operating lease liabilities305311357-1.9%-14.6%
Other liabilities4,4104,1025,303+7.5%-16.8%
Total liabilities and equity29,20828,33028,313+3.1%+3.2%
Fixed assets3,0763,0993,211-0.7%-4.2%
Goodwill6,4916,4936,486-0.0%+0.1%
Intangible assets9,3329,4689,806-1.4%-4.8%
Investments97.6n/an/a
Cash and equivalents3,8632,7591,699+40.0%+127.3%
Inventory2,2092,2742,469-2.9%-10.5%
Other assets4,1394,2384,643-2.3%-10.8%
Total assets29,20828,33028,313+3.1%+3.2%

Questions

What was Biogen's revenue in Q3 FY2025?

Biogen (BIIB) reported revenue of $2.5 billion for Q3 FY2025, the quarter ended 30 September 2025, up 2.8% on the same quarter a year earlier.

How much did Biogen earn in Q3 FY2025?

Net income for Q3 FY2025 was $466 million, up 20.1% on the year, and diluted earnings per share $3.17.

When did Biogen report Q3 FY2025 results?

Biogen filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 30 October 2025.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022 †Q2 FY2022Q3 FY2022Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024 †Q2 FY2024 †Q3 FY2024 †Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue2,7342,5322,5892,5082,5442,4632,4562,5302,3862,2902,4652,4662,4552,4312,6462,5352,2792,4782,7362,804
Cost of revenue660754484470571663593660618542546639584629605674496661777748
Gross profit2,0741,7782,1052,0391,9731,8001,8631,8711,7681,7481,9191,8271,8711,8022,0401,8601,7841,8171,9592,056
Gross margin76%70%81%81%78%73%76%74%74%76%78%74%76%74%77%73%78%73%72%73%
R&D700552529549602571584736571445505516532434399436509539530574
SG&A788635573563633605548788608582554588680572584595682607710752
Operating income5876111,2701,371604438708-141292465699451292311744557-56.0378132-9.0
Operating margin21%24%49%55%24%18%29%-6%12%20%28%18%12%13%28%22%-2%15%5%-0%
Interest expense66.266.165.859.954.862.549.163.871.569.261.359.860.060.072.667.467.567.682.387.5
Pre-tax income4053471,2701,371604438708-141292465699451292311744557-56.0378132-9.0
Tax rate109%36%17%17%9%12%16%n/a15%15%16%14%9%23%15%16%n/a15%26%n/a
Net income3683041,0581,135550388592-68.1250393584388267240635466-48.932097.5-20.6
Net margin13%12%41%45%22%16%24%-3%10%17%24%16%11%10%24%18%-2%13%4%-1%
Diluted EPS$2.50$2.06$7.24$7.84$3.79$2.67$4.07-$0.47$1.71$2.70$4.00$2.66$1.83$1.64$4.33$3.17-$0.33$2.15$0.66-$0.14
Operating cash flow838162736661-17545548759212.55536269367612591611,272512646449641
Capital expenditure51.657.936.959.186.466.671.074.265.245.933.535.039.337.126.646.243.951.240.940.4
Free cash flow787104700602-261389416518-52.75075929017222221341,226468594408600
Buybacks0.00.05002500.0n/an/a0.0n/an/an/an/an/an/an/an/an/an/an/an/a
Shares outstanding147m146m145m144m144m145m145m145m145m146m146m146m146m147m147m147m147m148m148m148m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2025, filed 30 October 2025: the filing.